Dr. Jingwu Zang received his medical degree from Shanghai JiaoTong University School of Medicine and a PhD in Neuroimmunology in Belgium, where he started his illustrious pursuit of an immune-therapy for autoimmune disease (multiple sclerosis) through basic and clinical research. Dr. Zang was a post-doctoral fellow of the US National MS Society at Harvard Medical School and later joined the faculty at Baylor College of Medicine as a professor of Neurology and the research director of Multiple Sclerosis Centre in Houston. He holds an active medical license in the State of Texas in US and was the founder of Opexa Pharmaceuticals, now listed on NASDAQ. In his career after moving back to China, Dr. Zang established the Institute of Health Sciences with Chinese Academy of Sciences as the founding director and co-founded the Institute Pasteur Shanghai, a partnership institute of the Chinese Academy of Sciences and Institute Pasteur Paris. Dr. Zang published over 150 scientific papers including in Science, Nature Medicine, Nature Immunology, and book chapters in the area of immunology and received many awards for the scientific works he led in US and China. He joined GlaxoSmithKline in 2007 as SVP and founded GSK’s R&D Centre in China and later became GSK’s global head of Neurosciences Therapy Area. In 2013, Dr. Zang was appointed as CSO of Simcere pharmaceuticals and President of BioSciKin, an open drug innovation organization based in Nanjing, China. Dr. Zang founded the Third Venture Biotechnologies together with the other members of the team in 2014.